Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
arcticnovartis

  • Phase III NETTER-2 trial met primary endpoint of improvement in progression-free survival (PFS) and key secondary endpoint of objective response rate (ORR) in patients with Grade 2 and 3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who received first line treatment with Lutathera® in combination with long-acting octreotide, versus high-dose long-acting octreotide alone1,2
  • Lutathera is the first radioligand therapy (RLT) to demonstrate clinically meaningful benefit in a
/by
Novartis confirms Sandoz Spin-off for October 4, 2023

Novartis confirms Sandoz Spin-off for October 4, 2023
arcticnovartis

  • Sandoz shares (SDZ) to be listed and traded on SIX Swiss Exchange; ADRs to be traded on OTCQX®, first trading day October 4, 2023
  • Sandoz to be included in key Swiss market indices
  • Investment grade credit rating for Sandoz confirmed: Moody’s, Baa2; S&P, BBB
  • Debt financing of USD 3.75 billion (in various currencies) secured for Sandoz, supported by USD 1.25 billion revolving credit facility
  • Spin-off to be completed by way of a 1:5 distribution of Sandoz shares to Nov
/by
Novartis statement on collaboration and license agreement for tislelizumab with BeiGene, Ltd.

Novartis statement on collaboration and license agreement for tislelizumab with BeiGene, Ltd.
weberfr8

/by
Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab

Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab
arcticnovartis

  • Positive CHMP opinion based on comprehensive package of analytical, pre-clinical and clinical data
  • Breast and gastric cancers are among most common types of cancer, accounting together for nearly half a million new cases every year in Europe alone1,2
  • Sandoz is committed to accelerating access to potentially life-changing treatments and continues to strengthen its oncology and supportive care portfolio

Basel, September 18, 2023 —

/by
Aktionärinnen und Aktionäre von Novartis stimmen dem geplanten 100% igen Spin-off von Sandoz zu

Aktionärinnen und Aktionäre von Novartis stimmen dem geplanten 100% igen Spin-off von Sandoz zu
arcticnovartis

  • Die Aktionärinnen und Aktionäre stimmen dem geplanten 100%igen Spin-off von Sandoz, dem Generika- und Biosimilars-Geschäft von Novartis, zu.
  • Die Aktionärinnen und Aktionäre stimmen ausserdem einer Herabsetzung des Aktienkapitals im Zusammenhang mit dem Spin-off zu.
  • Die Aktionärinnen und Aktionäre von Novartis und Inhaberinnen und Inhaber der Novartis ADR erhalten durch die Ausschüttung einer Sachdividende eine Sandoz Aktie für jeweils fünf Novartis Aktien oder ein Sandoz ADR für jeweils fünf Novartis ADRs.
/by
Novartis to present broad range of portfolio data at ECTRIMS, reinforcing long-standing commitment to people living with multiple sclerosis
  • Novartis will present 41 abstracts from a wide-ranging multiple sclerosis (MS) portfolio, including new data on Kesimpta® (ofatumumab) and Mayzent® (siponimod)

  • Novartis will be commencing Phase III pivotal trials investigating remibrutinib in RMS. Remibrutinib is a highly selective, potent oral BTK inhibitor with a potential best-in-class profile1
  • Late-breaking safety data will be presented, including outcomes of COVID-19 in relapsing forms of …
/by
Novartis to present broad range of portfolio data at ECTRIMS, reinforcing long-standing commitment to people living with multiple sclerosis
  • Novartis will present 41 abstracts from a wide-ranging multiple sclerosis (MS) portfolio, including new data on Kesimpta® (ofatumumab) and Mayzent® (siponimod)

  • Novartis will be commencing Phase III pivotal trials investigating remibrutinib in RMS. Remibrutinib is a highly selective, potent oral BTK inhibitor with a potential best-in-class profile1
  • Late-breaking safety data will be presented, including outcomes of COVID-19 in relapsing forms of …
/by
Sandoz Resolves Legacy Federal Government Civil Investigation in the U.S. Regarding Generic Drugs
  • Company previously disclosed settlement agreement in principle and fully provisioned for this resolution

Basel, October 1, 2021 – Sandoz Inc., the U.S. subsidiary of Sandoz, has entered a settlement agreement with the Civil Division of the U.S. Department of Justice (DOJ) concerning the Department’s years-long pricing investigation into the U.S. generic drug industry. This settlement is an expected outcome of the resolution the company reached in March 2020 with the DOJ Antitrust Division regarding the same investigation and underlying …

/by
Enabling our associates to work safely on our sites

As a leading healthcare company, Novartis is playing an important part by supporting vaccination to help overcome the pandemic. The safety of all associates, our customers, business partners and the communities where we run our operations remain a top priority for us. As company we have agreed on a long-term strategy supporting the global vaccination efforts and the COVID-19 vaccines are proven to be a powerful tool enabling us to move back to a more regular life.

In countries, where sufficient vaccine is available – and where it is in line with local law and regulations – we …

/by
Novartis data show rapid and effective disease activity control with remibrutinib (LOU064) in patients with chronic spontaneous urticaria
  • Results from a Phase IIb study show all remibrutinib doses provided significant improvements in UAS7 change from baseline at week 4 and week 12 compared to placebo, and a favorable safety profile across the entire dose range tested
  • All doses provided clinically meaningful improvements with respect to the proportion of patients achieving UAS7=0 (complete absence of hives and itch) and UAS7≤6 (well-controlled disease activity) vs. placebo over the treatment period, starting as early as Week 1

…

/by